TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31805855

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB) with 0.25% bupivacaine, repeated bilateral QLB for postoperative analgesia.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Continuous epidural analgesia with 6 ml/h of 0.25% bupivacaine during surgery and 6 ml/h of 0.125% bupivacaine for 24 h post-surgery.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB) with 0.25% bupivacaine.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Continuous epidural analgesia.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB).
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB) and continuous epidural analgesia.
Number of subjects: 62
Study: 28089476

Group type: EXPERIMENTAL
Intervention: ADMA levels (0.9±0.2μmol/L)
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Highest ADMA quintile (≥1.07μmol/L)
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: SDMA levels (4.3±1.4μmol/L)
Number of subjects: 1276
Study: 26149722

Group type: EXPERIMENTAL
Intervention: Daily SMS messages (direct, PIN-protected, coded) and transportation reimbursements (about $6 USD) for participants returning within seven days.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (pre-intervention period) with no SMS messages or transportation reimbursements.
Number of subjects: 183
Study: 24047438

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (AZT) 1000 mg orally
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZT) 500 mg daily for 9 and 14 days
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Doxycycline (DOX) 200 mg for 21 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 20819978

Group type: COMPARATOR
Intervention: Psilocybin (0.2 mg/kg)
Number of subjects: 12
Study: 19789402

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 17944893

Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus 400‐mL oral nutritional supplements daily for 6 weeks
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15547534

Group type: EXPERIMENTAL
Intervention: Foley catheter balloon inflated with 80 mL of sterile saline
Number of subjects: 203

Group type: COMPARATOR
Intervention: Foley catheter balloon inflated with 30 mL of sterile saline
Number of subjects: 203
Study: 11675190

Group type: EXPERIMENTAL
Intervention: Pleural tenting
Number of subjects: 20

Group type: COMPARATOR
Intervention: No pleural tenting (Control)
Number of subjects: 20
Study: 9154856

Group type: EXPERIMENTAL
Intervention: Chest wall vibration (CW) during hypercapnia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chest wall vibration (CW) during exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Deltoid vibration (DV) during hypercapnia
Number of subjects: 10

Group type: COMPARATOR
Intervention: No vibration (NV) during hypercapnia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Deltoid vibration (DV) during exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No vibration (NV) during exercise
Number of subjects: 10
Study: 7696154

Group type: EXPERIMENTAL
Intervention: Image analysis of DNA ploidy in colorectal carcinoma specimens
Number of subjects: 19
Study: 3305744

Group type: EXPERIMENTAL
Intervention: Combined modality approach in rectal carcinoma patients (stages B2 and C)
Number of subjects: 0
Study: 31239591

Group type: EXPERIMENTAL
Intervention: Gastric Lavage (GL)
Number of subjects: 0
Study: 29234747

Group type: EXPERIMENTAL
Intervention: Flapless implant placement
Number of subjects: 92

Group type: COMPARATOR
Intervention: Flap implant placement
Number of subjects: 92
Study: 26712786

Group type: EXPERIMENTAL
Intervention: MT10107
Number of subjects: 25

Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 25
Study: 23426035

Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention (reduced‐energy, low‐glycemic load, high‐fiber diet with behavioral change education)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Structured weight‐maintenance program
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Intervention worksites (not enrolled in weight‐loss program)
Number of subjects: 133
Study: 21296838

Group type: EXPERIMENTAL
Intervention: Real-time audio and visual feedback during CPR
Number of subjects: 1586

Group type: COMPARATOR
Intervention: No feedback during CPR
Number of subjects: 1586
Study: 19673983

Group type: EXPERIMENTAL
Intervention: Biophage-PA (therapeutic bacteriophage preparation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biophage-PA
Number of subjects: 24
Study: 16495395

Group type: EXPERIMENTAL
Intervention: Itopride 50 mg three times daily
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Itopride 100 mg three times daily
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Itopride 200 mg three times daily
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Itopride (combined doses)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Itopride (100 mg and 200 mg)
Number of subjects: 554
Study: 15100202

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG) with cardiopulmonary bypass
Number of subjects: 200
Study: 14616590

Group type: EXPERIMENTAL
Intervention: AM149 1% (new formulation of propofol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Disoprivan 1% (standard formulation of propofol)
Number of subjects: 30
Study: 10808691

Group type: EXPERIMENTAL
Intervention: Chula Mental Test (CMT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clock-Drawing Test (CDT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simultaneous application of CDT and CMT
Number of subjects: 48
Study: 8989072

Group type: EXPERIMENTAL
Intervention: Monitored exercise training
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Coached exercise training
Number of subjects: 51
Study: 1637794

Group type: EXPERIMENTAL
Intervention: Fat/cholesterol supplement (31 g fat, 650 mg cholesterol)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fat/cholesterol supplement
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fat-free supplement
Number of subjects: 51
Study: 3881654

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional treatment (azathioprine, prednisone, antithymocyte immunoglobulin)
Number of subjects: 34
Study: 31058977

Group type: EXPERIMENTAL
Intervention: HSV529 vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29781955

Group type: EXPERIMENTAL
Intervention: Family-centered care intervention (n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 61
Study: 26419905

Group type: EXPERIMENTAL
Intervention: Participation in the study
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Facilitators of participation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Barriers to participation
Number of subjects: 26
Study: 24373998

Group type: EXPERIMENTAL
Intervention: PT302 (4 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PT302 (0.5 mg, 1 mg, 2 mg, 4 mg)
Number of subjects: 34
Study: 22990142

Group type: EXPERIMENTAL
Intervention: Escitalopram alone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Escitalopram + IPT
Number of subjects: 86

Group type: COMPARATOR
Intervention: Escitalopram alone and Escitalopram + IPT
Number of subjects: 86
Study: 20160750

Group type: EXPERIMENTAL
Intervention: FA‐ADEK (fat‐soluble vitamins A,D,E,K plus fatty acids alpha‐linolenic acid (ALA), docosahexaenoic acid (DHA) and medium‐chain triglycerides)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ADEK (fat‐soluble vitamins A,D,E,K)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FA‐ADEK
Number of subjects: 48

Group type: COMPARATOR
Intervention: ADEK
Number of subjects: 48
Study: 18839781

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART; zidovudine [ZDV], lamivudine, and nevirapine [NVP])
Number of subjects: 58

Group type: COMPARATOR
Intervention: Short-course ZDV plus single-dose NVP (ZDV/NVP)
Number of subjects: 58
Study: 16025317

Group type: EXPERIMENTAL
Intervention: zopiclone (7.5 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: lormetazepam (1 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: zolpidem (10 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 11986476

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (</=3 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (single-dose or 1-day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (3-day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Long-course antibiotic therapy (7-14 days)
Number of subjects: 16
Study: 10524723

Group type: EXPERIMENTAL
Intervention: Experimental group received additional information about stop signals (three oral, one written) before injections.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group received standard information leaflet only.
Number of subjects: 36
Study: 7761218

Group type: EXPERIMENTAL
Intervention: Chemotherapy at home
Number of subjects: 14

Group type: COMPARATOR
Intervention: Chemotherapy in the hospital
Number of subjects: 14
Study: 2148014

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 20 mg TID
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Domperidone (DP) 20 mg TID
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of MPA and DP
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6985836

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily x 3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no Levamisole)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All patients (100 total)
Number of subjects: 100
Study: 31826731

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 182
Study: 31752785

Group type: EXPERIMENTAL
Intervention: 7-day mobile health education intervention
Number of subjects: 3360
Study: 28954877

Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality (TT + VR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 34
Study: 25491704

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy only
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy combined with motivational interviewing and a peer support group
Number of subjects: 16
Study: 24410783

Group type: EXPERIMENTAL
Intervention: 24-hour telephone specialist support line
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study: 21571149

Group type: EXPERIMENTAL
Intervention: Hydrogel-coated coils
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control (bare platinum coils)
Number of subjects: 499
Study: 19906763

Group type: EXPERIMENTAL
Intervention: TENS + exercise
Number of subjects: 109

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo stimulation + exercise
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study: 16951028

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (ciprofloxacin)
Number of subjects: 520000
Study: 14764980

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 10
Study: 11500190

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 328
Study: 9737478

Group type: EXPERIMENTAL
Intervention: Enoxaparin, ticlopidine, and aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin anticoagulant treatment
Number of subjects: 0
Study: 8144734

Group type: EXPERIMENTAL
Intervention: Braun Plak Control electric toothbrush
Number of subjects: 77

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 77
Study: 3416147

Group type: EXPERIMENTAL
Intervention: Audiocassette tape
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Self management booklet
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Both the book and tape
Number of subjects: 177

Group type: COMPARATOR
Intervention: Neither (control group)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Book alone
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: All groups given the material
Number of subjects: 177
Study: 1332102

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-2 and lymphokine-activated killer cells
Number of subjects: 8

Group type: COMPARATOR
Intervention: No active treatment (Control)
Number of subjects: 8
Study: 718066

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy and surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Surgery and postoperative radiation therapy
Number of subjects: 110
Study: 31449857

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 29340496

Group type: EXPERIMENTAL
Intervention: 24-month supervised maintenance exercise program (24MME group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 27-month physical activity counseling program (27MPAC group)
Number of subjects: 63
Study: 25202849

Group type: EXPERIMENTAL
Intervention: %HRR before allo‐HCT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: %HRmax before allo‐HCT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: %VO2max before allo‐HCT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: %HRR 180 days after allo‐HCT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: %HRmax 180 days after allo‐HCT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: %VO2max 180 days after allo‐HCT
Number of subjects: 106
Study: 23047980

Group type: EXPERIMENTAL
Intervention: Modified Open Airways for Schools (OAS) asthma education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21718265

Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training
Number of subjects: 123

Group type: COMPARATOR
Intervention: Twice-weekly balance and tone exercises (control)
Number of subjects: 123
Study: 18640743

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 17322994

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Endoscopic papillary balloon dilation (EPBD)
Number of subjects: 180
Study: 12740733

Group type: EXPERIMENTAL
Intervention: Hypoxic training group (HG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxic training group (NG)
Number of subjects: 12
Study: 10952639

Group type: EXPERIMENTAL
Intervention: Nurse clerking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Senior house officer (SHO) clerking
Number of subjects: 60
Study: 8788535

Group type: EXPERIMENTAL
Intervention: Cognitive coping skills training (three 45-min sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Disease-education control (three 45-min didactic-discussion sessions about SCD)
Number of subjects: 64
Study: 1281624

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 30
Study: 6690008

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (OK-432)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 211
Study: 30626270

Group type: EXPERIMENTAL
Intervention: PADS intervention (lesson plans and activities embedded into Massachusetts early learning standards, implemented for 4 days per week for 12 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (usual curriculum)
Number of subjects: 114
Study: 27388250

Group type: EXPERIMENTAL
Intervention: Transepithelial CXL
Number of subjects: 144

Group type: COMPARATOR
Intervention: Epithelium-off CXL
Number of subjects: 144
Study: 26363985

Group type: EXPERIMENTAL
Intervention: Locoregional treatment
Number of subjects: 350

Group type: COMPARATOR
Intervention: No locoregional treatment
Number of subjects: 350
Study: 23872530

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration training (WBV) in adolescents with Down syndrome (VDSG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Whole Body Vibration training (WBV) in adolescents without Down syndrome (VCG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No Whole Body Vibration training (nVDSG) in adolescents with Down syndrome
Number of subjects: 57

Group type: COMPARATOR
Intervention: No Whole Body Vibration training (nVCG) in adolescents without Down syndrome
Number of subjects: 57
Study: 21156001

Group type: EXPERIMENTAL
Intervention: Low-calcium diet + probiotic (2 g/kg diet)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-calcium diet + prebiotic (2 g/kg diet)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-calcium diet + synbiotic (mix of probiotic and prebiotic, each 2 g/kg diet)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-calcium diet + organic acid (1.5 g/kg diet)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-calcium diet (0.67%) without any additive
Number of subjects: 25

Group type: COMPARATOR
Intervention: Basal diet containing recommended level of calcium (0.9%)
Number of subjects: 25
Study: 19922882

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enalapril (5 mg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both telmisartan and enalapril
Number of subjects: 70
Study: 17097814

Group type: EXPERIMENTAL
Intervention: exercise+nicotine patch
Number of subjects: 142

Group type: COMPARATOR
Intervention: exercise+no nicotine patch
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy (CBT)+nicotine patch
Number of subjects: 142

Group type: COMPARATOR
Intervention: CBT+no nicotine patch
Number of subjects: 142
Study: 14993020

Group type: EXPERIMENTAL
Intervention: Age group 18 to 30 years
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Age group 31 to 40 years
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Age group 41 to 50 years
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Age group 51 to 60 years
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Age group 61 to 70 years
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: All age groups
Number of subjects: 3076
Study: 11252465

Group type: EXPERIMENTAL
Intervention: Four-week static stretching protocol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eight-week static stretching protocol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 9869343

Group type: EXPERIMENTAL
Intervention: Free conjunctival autograft (FCG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Postoperative strontium 90 (90Sr) beta-irradiation
Number of subjects: 54
Study: 8363392

Group type: EXPERIMENTAL
Intervention: Enoxacin (200 mg/12 h for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefuroxime axetil (125 mg/12 h for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxacin and Cefuroxime axetil
Number of subjects: 0
Study: 3534857

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg every 8 hours for 1 month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin 0.25 mg once a day for 1 month
Number of subjects: 0
Study: 31291923

Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment (MBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual Clinical Care (UCC)
Number of subjects: 36
Study: 26888146

Group type: EXPERIMENTAL
Intervention: recombinant human (rh)IGF‐I/rhIGF binding protein‐3 (IGFBP‐3) complex (30 mg/day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: recombinant human (rh)IGF‐I/rhIGF binding protein‐3 (IGFBP‐3) complex (60 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: recombinant human (rh)IGF‐I/rhIGF binding protein‐3 (IGFBP‐3) complex (30 mg/day or 60 mg/day)
Number of subjects: 56
Study: 26006260

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) with chloroquine taken once
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three courses of SP with azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Malaria prevention regimen
Number of subjects: 0
Study: 24081940

Group type: EXPERIMENTAL
Intervention: Venlafaxine and soy protein powder
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Venlafaxine and milk protein powder
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Soy protein powder and placebo pill
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Venlafaxine and placebo pill
Number of subjects: 120
Study: 21725874

Group type: EXPERIMENTAL
Intervention: 2% KZC and 2% TET cream (KCZ + TET group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 2% KZC cream (KCZ group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 2% TET cream (TET group)
Number of subjects: 97
Study: 19370276

Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg/kg and Dexamethasone 10 mg (MD group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg/kg (M group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (D group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous normal saline (S group)
Number of subjects: 80
Study: 16468112

Group type: EXPERIMENTAL
Intervention: Structured outpatient follow-up care consisting of 12 half-hour consultations by primary care physicians utilizing a modular consultation guideline and an internet-based training programme.
Number of subjects: 521

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Structured outpatient follow-up care.
Number of subjects: 521
Study: 15329905

Group type: EXPERIMENTAL
Intervention: Radiotherapy (20 Gray [Gy]/10 fractions to a modified pelvic volume)
Number of subjects: 22